Drug intelligence / Profile preview

ASC 41 Placebo

Development stage: Unknown
Lead developer: Gannex Pharma
Modality: Small Molecules
Administration: Oral

Overview

ASC 41 Placebo is the inert control arm used in clinical trials for ASC41, a liver-targeted thyroid hormone receptor beta (THR-β) agonist developed by Gannex Pharma (a subsidiary of Ascletis Pharma). As a placebo, it contains no active pharmaceutical ingredient and is designed to match the appearance and administration of the ASC41 oral tablets. It was utilized in Phase Ib studies to evaluate the safety, tolerability, and pharmacodynamics of ASC41 in overweight and obese subjects with elevated LDL-C, as well as in trials for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

Beyond the preview

Go deeper on ASC 41 Placebo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASC 41 Placebo.

Explore the full profile